http://orcid.org/0000-0002-9816-6302
References
- Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology. 2006;1:142–146.
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Acute Lymphoblastic Leukemia Version 2.2019. 2019; May 15.
- Drachtman RA, Cole PD, Golden CB, et al. Dextromethrophan is effective in treatment of subacute methotrexate neurotoxicity. J Pediatr Hematol Oncol. 2002;19(5):319–327.
- FDA. Methotrexate Injection [package insert]. Lake Forest (IL): Hospira; 2011.
- Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4(2):87–101.
- Jacobs SA, Bleyer WA, Chabner BA, et al. Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet. 1975;1:455–456.
- Sallah S, Hanrahan LR, Phillips DL. Intrathecal methotrexate-induced megaloblastic anemia in patients with acute leukemia. Arch Pathol Lab Med. 1991;123:774–777.
- Quinn CT, Griener JC, Bottiglieri T, et al. Methotrexate, homocysteine, and seizures. JCO. 1998;16(1):393–394.
- Valle DA, Kakehasi FM, Siqueira CM, et al. Stroke-like encephalopathy following high-dose intravenous methotrexate in an adolescent with osteosarcoma: a case report. Rev Bras Hematol Hemoter. 2016;38(4):364–367.
- Pavlidou E, Pavlou E, Anastasiou A, et al. Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: a case report and literature update. Quant Imaging Med Surg. 2016;6(5):605–611.
- FDA. Cytarabine injection [package insert]. New York (NY): Pfizer; 2011.